tirzepatide surmount-1 trial weight loss non-diabetic Gastrointestinal tolerability and reduction associated with in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT‐1 to ‐4 trials - Rubino - 2025 Tirzepatide for the Maintenance of

When to speak to your GP If you notice worsening anxiety, new panic attacks, persistent low mood, or thoughts of self-harm after starting Mounjaro, speak to your GP promptly

Most are mild to moderate and improve as your body adjusts during dose escalation

Rybelsus is now the first and only oral glucagon-like peptide 1 receptor agonist (GLP-1 RA) mimicking a natural hormone in your body that helps regulate blood sugar, appetite, and digestion available in the EU for type 2 diabetes with a proven cardiovascular benefit, states Novo Nordisk

Better results, starting now: your nutrition roadmap for GLP-1 therapy Obesity is a defining health challenge of our time